Lercanidipine hydrochloride

CLINICAL USE


Calcium-channel antagonist:Mild to moderate hypertension

DOSE IN NORMAL RENAL FUNCTION

  • 10 to 20 &nbsp &nbsp : mg daily

    PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :648.2
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :>98
  • %Excreted unchanged in urine &nbsp &nbsp : 50 (as metabolites)

  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :No data

  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :8–10/Increased

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50 &nbsp &nbsp : Use small doses and titrate to response
  • 10 to 20 &nbsp &nbsp : Use small doses and titrate to response
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Use small doses and titrate to response

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in GFR <10 mL/min

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unlikely to be dialysed. Dose as in GFR <10 mL/min
  • HDF/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL/min
  • CAV/VVHD &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in GFR 10 to 20 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • Anaesthetics: enhanced hypotensive effect
  • Antibacterials: avoid concomitant use with erythromycin
  • Anti-epileptics: effect reduced by carbamazepine, barbiturates, phenytoin and primidone
  • Antifungals: metabolism possibly inhibited by itraconazole and ketoconazole – avoid concomitant useAntihypertensives: enhanced hypotensive effect, increased risk of first dose hypotensive effect of post-synaptic alpha-blockers
  • Antivirals: concentration increased by ritonavir – avoid concomitant useCardiac glycosides: digoxin concentration increased
  • Ciclosporin: concentration of both drugs may be increased – avoid concomitant use
  • Grapefruit juice: concentration increased – avoid concomitant useTheophylline: possibly increased theophylline concentration

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    Take before food

    OTHER INFORMATION

    Causes less peripheral oedema than other calcium-channel blockersLercanidipine hydrochloride.426 LETroZoLELetrozole

    CLINICAL USE


    Treatment of advanced breast cancer

    DOSE IN NORMAL RENAL FUNCTION

    2.5 mg daily

    PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :285.3
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :60
  • %Excreted unchanged in urine &nbsp &nbsp : 6

  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :1.87

  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :48/Unchanged

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Probably dialysed. Use with caution

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. Use with caution
  • HDF/high flux &nbsp :Dialysed. Use with caution
  • CAV/VVHD &nbsp &nbsp &nbsp:Probably dialysed. Use with caution

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • None known

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    –.
    Tags:

    • Related News

    sotalol hydrochloride.txt

    tazocin.txt